Meta-Analysis
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2793-2803
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2793
Meta-analysis of transarterial chemoembolization combined with cryoablation vs transarterial chemoembolization alone for ≥ 5 cm hepatocellular carcinoma
Jie-Fei Cheng, Qiu-Lian Sun, Ling Tang, Xin-Jian Xu, Xiang-Zhong Huang
Jie-Fei Cheng, Department of Radiology, The Fifth People’s Hospital of Taizhou, Taizhou 225300, Jiangsu Province, China
Qiu-Lian Sun, Department of Radiology, The Fifth People’s Hospital of Suzhou, Suzhou 215100, Jiangsu Province, China
Ling Tang, Department of Radiology, The Fourth People’s Hospital of Taizhou, Taizhou 225300, Jiangsu Province, China
Xin-Jian Xu, Xiang-Zhong Huang, Department of Interventional Radiology, Jiangyin People Hospital, Jiangyin 214400, Jiangsu Province, China
Co-first authors: Jie-Fei Cheng and Qiu-Lian Sun.
Co-corresponding authors: Xin-Jian Xu and Xiang-Zhong Huang.
Author contributions: Cheng JF and Sun QL are contributed equally to this work and should be considered co-first authors. Cheng JF made significant contributions to data collection and initial drafting of the manuscript; Sun QL was responsible for literature review, study design, and collaborated closely with other authors; Cheng JF, Sun QL, and Tang L contributed to the data analysis; Tang L provided valuable guidance and suggestions throughout the research process, and contributed to the interpretation of findings; Xu XJ is the corresponding author of this study and as the principal investigator, made significant contributions in research concept generation, guidance, supervision, and manuscript review and revision. His expertise and skills are of great significance for the accuracy and reliability of the research findings; Huang XZ is a co-corresponding author of this study. He was responsible for writing critical sections of the manuscript and provided effective technical support throughout the research process. His efforts played a key role in the smooth progress of the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xin-Jian Xu, MD, Doctor, Department of Interventional Radiology, Jiangyin People Hospital, No. 3 Yingrui Road, Jiangyin 214400, Jiangsu Province, China. qiezinb@126.com
Received: December 11, 2023
Revised: March 1, 2024
Accepted: April 16, 2024
Published online: June 15, 2024
Processing time: 187 Days and 1.3 Hours
Core Tip

Core Tip: To compare the efficacy and safety of transarterial chemoembolization (TACE) combined with cryoablation (CRA) vs TACE alone in the treatment of hepatocellular carcinoma (HCC) with a diameter of ≥ 5 cm. Compared with TACE-alone treatment, TACE + CRA combined treatment not only improves the immune function of HCC patients with a diameter of ≥ 5 cm, but also enhances the therapeutic efficacy and long-term survival rate, without increasing the risk of complications. Therefore, TACE + CRA combined treatment may be a more recommended treatment for patients with HCC with a diameter of ≥ 5 cm.